Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT 1 R) blockers, current …

This article provides a contemporary review and a new perspective on the role of neprilysin
inhibition in heart failure (HF) in the context of recent clinical trials and addresses potential …

After its discovery in the early 1980s, the natriuretic peptide (NP) system has been
extensively characterized and its potential influence in the development and progression of …

Heart failure affects≈ 5.7 million people in the United States alone. Angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists …

Background LCZ696 is a first-in-class inhibitor of the angiotensin II receptor and neprilysin.
We aimed to establish whether the dual actions of LCZ696 lead to further lowering of blood …

Background—Angiotensin receptor neprilysin inhibitors (ARNi), beyond blocking
angiotensin II signaling, augment natriuretic peptides by inhibiting their breakdown by …

The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of
hormones possessing relevant haemodynamic and anti-remodelling actions in the …

Hypertension and heart failure (HF) are common diseases that, despite advances in medical
therapy, continue to be associated with high morbidity and mortality. Therefore, innovative …

Neprilysin is an enzyme that contributes to the breakdown of the biologically active
natriuretic peptides and several other vasoactive compounds. Inhibiting neprilysin has been …

Neprilysin has a major role in both the generation and degradation of bioactive peptides.
LCZ696 (valsartan/sacubitril, Entresto), the first of the new ARNI (dual-acting angiotensin …